Cell & Gene Therapy World 2017

Cell & Gene Therapy World Agenda

Loading
  1. Registration for Phacilitate Cell & Gene Therapy World 2018 opens
  1. Gala Welcome Drinks Reception on The Terrace
  1. Registration & Buffet Breakfast in the Exhibition Area
  1. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  2. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  3. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  4. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  5. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  1. Morning Coffee in the Exhibition Area
  1. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  2. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  3. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  4. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  5. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  6. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  7. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  1. Facing up to critical raw materials supply shortfalls - the single largest elephant in the commercial cell & gene therapy room?

    Supply Chain - Raw & Starting Materials
  2. Facing up to critical raw materials supply shortfalls - the single largest elephant in the commercial cell & gene therapy room?

    Supply Chain - Raw & Starting Materials
  3. Facing up to critical raw materials supply shortfalls - the single largest elephant in the commercial cell & gene therapy room?

    Supply Chain - Raw & Starting Materials
  1. Buffet Lunch in the Exhibition Area
  1. Engineering the next frontier in cellular immunotherapy: looking beyond CD19

    Emerging Science - Oncology
  2. Engineering the next frontier in cellular immunotherapy: looking beyond CD20

    Emerging Science - Oncology
  3. Engineering the next frontier in cellular immunotherapy: looking beyond CD21

    Emerging Science - Oncology
  4. Engineering the next frontier in cellular immunotherapy: looking beyond CD22

    Emerging Science - Oncology
  5. Engineering the next frontier in cellular immunotherapy: looking beyond CD23

    Emerging Science - Oncology
  6. Engineering the next frontier in cellular immunotherapy: looking beyond CD24

    Emerging Science - Oncology
  7. Engineering the next frontier in cellular immunotherapy: looking beyond CD25

    Emerging Science - Oncology
  1. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  2. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  3. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  4. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  1. Afternoon Tea in the Exhibition Area
  1. Securing sufficient manufacturing capacity for a commercializing sector - what are the most viable short- and long-term solutions?

    Cell-based therapy
  2. Securing sufficient manufacturing capacity for a commercializing sector - what are the most viable short- and long-term solutions?

    Cell-based therapy
  1. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  2. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  3. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  4. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  5. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  6. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  7. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  1. How to maximize efficiency in raw and starting materials quality control/characterization?

    Supply Chain - Raw & Starting Materials
  2. How to maximize efficiency in raw and starting materials quality control/characterization?

    Supply Chain - Raw & Starting Materials
  3. How to maximize efficiency in raw and starting materials quality control/characterization?

    Supply Chain - Raw & Starting Materials
  1. Drinks Reception in the Exhibition Area
  1. Registration & Buffet Breakfast in the Exhibition Area
  1. Morning Coffee in the Exhibition Area
  1. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  2. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  3. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  4. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  5. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  6. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  1. Macro trends in investor, pharma and regulatory environments

    Cord Blood & Perinatal Stem Cells
  2. Macro trends in investor, pharma and regulatory environments

    Cord Blood & Perinatal Stem Cells
  3. Macro trends in investor, pharma and regulatory environments

    Cord Blood & Perinatal Stem Cells
  1. Buffet Lunch in the Exhibition Area
  1. Japan Partnering Lunch

  1. Highlighting and addressing 'critical path' issues in bringing vector manufacturing processes from Phase I/II to commercial scale

    Gene Therapy
  2. Highlighting and addressing 'critical path' issues in bringing vector manufacturing processes from Phase I/II to commercial scale

    Gene Therapy
  3. Highlighting and addressing 'critical path' issues in bringing vector manufacturing processes from Phase I/II to commercial scale

    Gene Therapy
  1. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  2. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  3. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  4. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  5. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  6. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  7. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  1. Tour of the Vein-to-Vein Supply Chain Hub

    Supply Chain - Cold chain and data integration/management
  1. Afternoon Tea in the Exhibition Area
  1. Comparing and contrasting current and emerging gene therapy production platforms and characterization tools

    Gene Therapy
  2. Comparing and contrasting current and emerging gene therapy production platforms and characterization tools

    Gene Therapy
  3. Comparing and contrasting current and emerging gene therapy production platforms and characterization tools

    Gene Therapy
  1. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  2. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  3. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  4. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  5. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  6. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  7. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  1. Supply chain scale up strategies and enabling technologies to minimize CoGs

    Supply Chain - Cold chain and data integration/management
  2. Supply chain scale up strategies and enabling technologies to minimize CoGs

    Supply Chain - Cold chain and data integration/management
  3. Supply chain scale up strategies and enabling technologies to minimize CoGs

    Supply Chain - Cold chain and data integration/management
  1. Close of Day 2: Evening Boat Party!
  1. Registration & Buffet Breakfast in the Exhibition Area
  1. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  2. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  3. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  4. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  1. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  2. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  3. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  4. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  5. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  6. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  1. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  2. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  3. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  4. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  5. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  6. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  1. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  2. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  3. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  4. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  5. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  1. Buffet Lunch in the Exhibition Area
  1. Envisioning the bioprocessing toolbox of the future: proactively planning tomorrow's solutions to meet both manufacturers and tool providers' strategic needs

    Cell-based therapy
  2. Envisioning the bioprocessing toolbox of the future: proactively planning tomorrow's solutions to meet both manufacturers and tool providers' strategic needs

    Cell-based therapy
  1. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  2. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  3. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  4. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  5. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  1. What progress in alleviating the cord blood & perinatal cell expansion bottleneck?

    Cord Blood & Perinatal Stem Cells
  2. What progress in alleviating the cord blood & perinatal cell expansion bottleneck?

    Cord Blood & Perinatal Stem Cells
  3. What progress in alleviating the cord blood & perinatal cell expansion bottleneck?

    Cord Blood & Perinatal Stem Cells
  1. Afternoon Tea in the Exhibition Area
  1. Close of Phacilitate Cell & Gene Therapy World 2018

  • "The event reflected the fantastic growing enthusiasm around cell and gene therapy, including small and large companies, investors and regulators. It was great to see everyone so engaged and so positive. The event really gives you the “pulse” of what is happening right now in cell and gene therapy."
    Anne-Virginie Eggimann,
    Vice President, Regulatory Science, Bluebird Bio, Inc
  • “Great program, great people, great venue.”
    Klaus Kühlcke
    Managing Director, EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.”
    Nathalie Clement
    Associate Director, Powell Gene Therapy Center, University of Florida
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • "It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives."
    Kurt Gielen
    Acquisition & Business Development Manager, BioMedical Materials, Chemelot Campus B.V.
  • “Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.”
    Steven Goodman
    Director, Strategy and Engagement, GSK